Hospital De Santa Maria E.P.E.
- Address
- lock Available on a paid plan
Oncology (Neoplasms)
Hospital De Santa Maria E.P.E. is active in oncology, testing new therapies for a range of solid tumors and blood‑derived cancers. The trials aim to improve survival, assess safety, and explore innovative treatment combinations.
- Breast cancer, including hormone‑positive and HER2‑positive subtypes
- Advanced solid tumors such as colorectal and bladder cancer
- Rare sarcomas like dedifferentiated liposarcoma
- High‑risk prostate cancer
With 39 trials and 59 investigators, the site contributes significantly to cancer research in Portugal.
Hematology & Blood Disorders
The department conducts hematology studies targeting malignant blood diseases, focusing on novel agents and immune‑based approaches to enhance treatment response.
- Acute myeloid leukemia with specific genetic markers
- Relapsed or refractory multiple myeloma
- Follicular lymphoma and chronic lymphocytic leukemia
- High‑risk myelodysplastic syndromes
These investigations seek to define optimal dosing and evaluate long‑term safety for patients with limited options.
Autoimmune & Inflammatory Diseases
Research at the site includes autoimmune disease trials that evaluate targeted therapies to reduce inflammation and modify disease progression.
- Rheumatoid arthritis and erosive hand osteoarthritis
- Psoriatic arthritis and atopic dermatitis
- Hidradenitis suppurativa and chronic graft‑versus‑host disease
- Inflammatory bowel disease such as Crohn’s disease
The goal is to provide patients with more effective and safer treatment alternatives.
Dermatology & Skin Disorders
Clinical work in dermatology focuses on severe skin conditions, testing biologic agents to improve skin integrity and quality of life.
- Moderate‑to‑severe atopic dermatitis
- Psoriasis and psoriatic arthritis overlap
- Rare disorders like fibrodysplasia ossificans progressiva
- Hidradenitis suppurativa
Safety and durability of response are key endpoints across these studies.
Pulmonary and Cardiovascular Diseases
The hospital’s trials in pulmonary and cardiovascular medicine evaluate therapies for high‑pressure and vascular disorders, aiming to lower morbidity.
- Pulmonary arterial hypertension (group I)
- Pulmonary hypertension associated with interstitial lung disease
- Heart failure with preserved ejection fraction secondary to pulmonary hypertension
- Investigational agents for pulmonary hypertension
Patients receive combination regimens to test whether early triple therapy improves risk status.
Metabolic and Genetic Disorders
Investigations in metabolism address inherited and metabolic conditions, seeking disease‑modifying treatments.
- Hereditary transthyretin amyloidosis
- Phenylketonuria and dietary management
- CDKL5 deficiency disorder
- Osteogenesis imperfecta and brittle bone disease
These studies often monitor biomarkers and functional outcomes to gauge therapeutic impact.
Neurology and Neurodegeneration
The site supports neurology trials that explore novel agents for neurodegenerative and movement disorders, focusing on safety and functional improvement.
- Huntington’s disease in prodromal stages
- Spinal muscular atrophy
- Early‑onset neurodevelopmental disorders
- Cognitive impairment in schizophrenia (as a neuropsychiatric overlap)
Long‑term follow‑up includes imaging and biomarker analysis to assess disease modification.
Psychiatry and Mental Health
Trials in psychiatry aim to improve cognitive and symptomatic outcomes for serious mental illnesses.
- Schizophrenia with cognitive deficits
- Adjunctive treatments for migraine with psychiatric comorbidities
- Evaluation of novel agents affecting mood and cognition
- Safety monitoring in long‑term psychiatric drug use
Research emphasizes both efficacy and tolerability to enhance patient quality of life.
Gastroenterology and Digestive Disorders
Gastro‑intestinal research at the center includes gastroenterology studies targeting chronic inflammatory disease and cancer of the digestive tract.
- Moderate to severe Crohn’s disease
- Metastatic colorectal cancer
- Resectable colon cancer with dMMR/MSI‑H status
- High‑risk non‑muscle invasive bladder cancer
These trials assess new drug combinations and peri‑operative strategies to improve disease‑free survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 120 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 119 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital De Santa Maria E.P.E.
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18Years or Older (CHOICES) | Universitair Medisch Centrum Utrecht | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 120 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 4 | Unknown | 2022-11-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.